European Heart Journal Advance Access published online on February 1, 2007
European Heart Journal, doi:10.1093/eurheartj/ehl489
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days
Deutches Herzzentrum, Technische Universitat Munchen, Munich, Germany
Received 25 September 2006; revised 27 November 2006; accepted 3 January 2007.
* Corresponding author. 1. Medizinische Klinik, Klinikum rechts der Isar, Isamaninger Str. 22, 81675 München, Germany. Tel: +49 89 4140 6660; fax: +49 89 4140 6668. E-mail address: beckerath{at}dhm.mhn.de
AIMS: We sought to test whether an increase in the clopidogrel maintenance dose results in increased inhibition of platelet aggregation.
METHODS AND RESULTS: Sixty patients after pre-treatment with 600 mg of clopidogrel and within 12 h after successful PCI were included in this trial. They were allocated to receive one of two clopidogrel daily maintenance doses (75 or 150 mg) for 30 days in a double-blind randomized manner. Platelet function was evaluated 30 days after the intervention with optical aggregometry and with a new point-of-care test (VerifyNowTM P2Y12 assay). Maximal 5 µM ADP-induced platelet aggregation 30 days after PCI in the group treated with 150 mg/day clopidogrel (45.1 ± 20.9%) was significantly lower than in the group treated with 75 mg/day (65.3 ± 12.1%; P < 0.001). The VerifyNowTM P2Y12 assay also indicated a higher degree of platelet function inhibition in the group treated with 150 mg/day (60.0 ± 72.0 P2Y12 Reaction Units) than in the group treated with 75 mg/day (117.0 ± 64.3 P2Y12 Reaction Units; P = 0.004).
CONCLUSION: Administration of a 150 mg oral maintenance dose of clopidogrel results in more intense inhibition of platelet aggregation than administration of the currently recommended 75 mg maintenance dose.
Key Words: Platelets • Pharmacology • Receptors • Antiplatelet agents • Thrombosis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Cattaneo Fast, potent, and reliable inhibition of platelet aggregation Eur. Heart J. Suppl., December 1, 2009; 11(suppl_G): G9 - G13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Verstuyft, T. Simon, and R. B. Kim Personalized medicine and antiplatelet therapy: ready for prime time? Eur. Heart J., August 2, 2009; 30(16): 1943 - 1963. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Tousoulis, A. Briasoulis, S. S Dhamrait, C. Antoniades, and C. Stefanadis Effective platelet inhibition by aspirin and clopidogrel: where are we now? Heart, May 1, 2009; 95(10): 850 - 858. [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. SABATINE Novel antiplatelet strategies in acute coronary syndromes Cleveland Clinic Journal of Medicine, April 1, 2009; 76(Suppl_1): S8 - S15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Aleil, L. Jacquemin, F. De Poli, M. Zaehringer, J.-P. Collet, G. Montalescot, J.-P. Cazenave, M.-C. Dickele, J.-P. Monassier, and C. Gachet Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention: Results From the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) Randomized Study J. Am. Coll. Cardiol. Intv., December 1, 2008; 1(6): 631 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.H. Lee, A. Arat, H. Morsi, H. Shaltoni, J.R. Harris, and M.E. Mawad Dual Antiplatelet Therapy Monitoring for Neurointerventional Procedures Using a Point-of-Care Platelet Function Test: A Single-Center Experience AJNR Am. J. Neuroradiol., August 1, 2008; 29(7): 1389 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Price, S. Endemann, R. R. Gollapudi, R. Valencia, C. T. Stinis, J. P. Levisay, A. Ernst, N. S. Sawhney, R. A. Schatz, and P. S. Teirstein Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur. Heart J., April 2, 2008; 29(8): 992 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Muller-Schunk, J. Linn, N. Peters, M. Spannagl, M. Deisenberg, H. Bruckmann, and T.E. Mayer Monitoring of Clopidogrel-Related Platelet Inhibition: Correlation of Nonresponse with Clinical Outcome in Supra-Aortic Stenting AJNR Am. J. Neuroradiol., April 1, 2008; 29(4): 786 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kereiakes and P. A. Gurbel Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 111 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Michelson P2Y12 Antagonism: Promises and Challenges Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): s33 - s38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang and B. Kanna A double blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days Eur. Heart J., February 1, 2008; 29(3): 423 - 424. [Full Text] [PDF]
|
|
|
|
|
|
N. von Beckerath, D. Sibbing, and A. Kastrati A double blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days: reply Eur. Heart J., February 1, 2008; 29(3): 424 - 424. [Full Text] [PDF]
|
|
|
|
|
|
R. F. Storey Variability of response to antiplatelet therapy Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A21 - A27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Wiviott, D. Trenk, A. L. Frelinger, M. O'Donoghue, F.-J. Neumann, A. D. Michelson, D. J. Angiolillo, H. Hod, G. Montalescot, D. L. Miller, et al. Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Thrombolysis in Myocardial Infarction 44 Trial Circulation, December 18, 2007; 116(25): 2923 - 2932. [Abstract] [Full Text] [PDF]
|
|